These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Ca2+]i and PKC-alpha are involved in the inhibitory effects of Ib, a novel nonpeptide AngiotensinII subtype AT1 receptor antagonist, on AngiotensinII-induced vascular contraction in vitro.
    Author: Wang Y, Wang W, Wang Q, Wu J, Xu J, Wu X.
    Journal: Biochem Biophys Res Commun; 2007 Dec 07; 364(1):118-23. PubMed ID: 17931598.
    Abstract:
    The vasoactive peptide AngiotensinII (AngII) is an important factor in the cardiovascular system, exerting most of its effects through AngII receptor type 1 (AT1). Ib, a new nonpeptide AT1 receptor antagonist, has been observed to play a positive role in the treatment of hypertension in preclinical tests. In this study, the inhibitory effects of Ib on AngII-induced vascular contraction in vitro were investigated, and its molecular mechanisms were further explored. In endothelium-denuded aortic rings from rabbits, Ib produced a rightward shift in the concentration-response curve for AngII with a decrease in the maximal contractile response and the pD2' was 7.29. In vascular smooth muscle cells (VSMCs), the specific binding of [125I]AngII to AT1 receptors was inhibited by Ib in a concentration-dependent manner with IC50 value of 0.96nM. Ib could inhibit both AngII-induced Ca2+ mobilization from internal stores and Ca2+ influx. Moreover, the translocation of PKC-alpha stimulated by AngII was inhibited by Ib. Thus, the inhibitory effects of Ib might be related with the depression on AngII-induced increase in [Ca2+]i and translocation of PKC-alpha through blocking AT1 receptors.
    [Abstract] [Full Text] [Related] [New Search]